- Home
- Products
- Customized FluoroAb™
- ERBB3
- Anti-ERBB3 MAb (Clone 8)-iFluor® 440 Succinimidyl Ester
Anti-ERBB3 MAb (Clone 8)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5870)
This product is comprised of an Human Anti-ERBB3 IgG1-kappa-[scFv-heavy-lambda]2 (Clone 8) labeled with iFluor® 440 Succinimidyl Ester. iFluor® 440 Succinimidyl Ester is a Green-fluorescent dye and it's excitation/emission is 403/427 nm.
- TARGET
- ANTIBODY
- DYE
- Name
- ERBB3
- Alternative Names
- ERBB3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); LCCS2; lethal congenital contracture syndrome 2; receptor tyrosine-protein kinase erbB-3; HER3; proto-oncogene-like protein c-ErbB-3; tyrosine kinase-type cell surface receptor HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; MGC88033;
- Overview
- This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized.
- Overview
- Human Anti-ERBB3 IgG1-kappa-[scFv-heavy-lambda]2 (Clone 8)
- Species Reactivity
- Human
- Name
- iFluor® 440 Succinimidyl Ester
- Color
- Green
- Excitation⁄Emission (nm)
- 434/480
- Detection method
- Fluorescent
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-Fibrin II-beta chain MAb (Clone 2)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS8417)
- Anti-LTA MAb (Clone 4)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2922)
- Anti-C. diff Toxin A MAb (Clone 3)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS4657)
- Anti-MET MAb (Clone 13)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS6020)
- Anti-CD22 MAb (Clone 33)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10114)
- Anti-Dabigatran MAb (Clone 2)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS7792)
- Zanolimumab-iFluor 594 (CAT#: ADC-FL-620)
- Anti-MET MAb (Clone 23)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1416)
- Anti-CMV MAb (Clone 9)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS3101)
- Anti-KIRD2 MAb (Clone 1)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS8431)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS5870. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-1127 | Anti-ERBB3 (Seribantumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2366 | Anti-ERBB3 (Duligotuzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2244 | Anti-ERBB3 (Duligotumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2370 | Anti-ERBB3 (Duligotuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2242 | Anti-ERBB3 (Duligotumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
